表紙
市場調查報告書

過敏性鼻炎治療藥的全球市場:2020年∼2024年

Global allergy rhinitis drugs market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 500858
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
過敏性鼻炎治療藥的全球市場:2020年∼2024年 Global allergy rhinitis drugs market 2020-2024
出版日期: 2020年03月17日內容資訊: 英文 120 Pages
簡介

全球過敏性鼻炎治療藥市場在2020年∼2024年的預測期間內,預計將以4%的年複合成長率增長,達到24億美元的規模。過敏性鼻炎的盛行率增加成為主要的市場成長要素。此外過敏性鼻炎的認識不斷提升,可望進一步促進市場的成長。

本報告提供全球過敏鼻炎治療藥市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2019年
  • 市場預測:2019-2024年的預測

波特的五力分析

各產品市場區隔

  • 市場區隔
  • 各產品比較:市場規模與預測2019-2024
  • 抗組織胺藥物
  • 鼻腔內皮質類固醇
  • 免疫療法
  • 其他
  • 各產品的市場機會

客戶形勢

  • 概要

各地區形勢

  • 各地區市場區隔
  • 各地區比較:市場規模與預測2019-2024
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲地區
  • 主要國家
  • 各地區的市場機會

成長要素,課題,及趨勢

  • 市場成長要素
  • 交易量的成長要素-需求主導型成長
  • 交易量的成長要素-供給主導型成長
  • 交易量的成長要素-外部要素
  • 交易量的成長要素-需求轉移到鄰近市場
  • 價格上升要素-通貨膨脹
  • 價格成長要素-從低價格單位轉變到高價格單位
  • 市場課題
  • 市場趨勢

業者情勢

  • 概要
  • 形勢的創新

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Alcon Inc.
  • ALK-Abello AS
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stallergenes Greer Ltd.

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR41321

Technavio has been monitoring the global allergy rhinitis drugs market 2020-2024 and it is poised to grow by USD 2.4 bn during 2020-2024, progressing at a CAGR of 4% during the forecast period. Our reports on global allergy rhinitis drugs market 2020-2024 provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of allergic rhinitis. In addition, increasing awareness about allergic rhinitis is anticipated to boost the growth of the global allergy rhinitis drugs market 2020-2024 as well.

Market Segmentation

Technavio's ‘ global allergy rhinitis drugs market 2020-2024 ’ is segmented as below:

Product:

  • Antihistamines
  • Intranasal Corticosteroids
  • Immunotherapies
  • Others

Geographic segmentation

  • APAC
  • Europe
  • MEA
  • North America
  • South America

Key Trends for global allergy rhinitis drugs market 2020-2024 growth

This study identifies increasing awareness about allergic rhinitis as the prime reasons driving the global allergy rhinitis drugs market 2020-2024 growth during the next few years.

Prominent vendors in global allergy rhinitis drugs market 2020-2024

We provide a detailed analysis of around 25 vendors operating in the global allergy rhinitis drugs market 2020-2024, including some of the vendors such as Alcon Inc., ALK-Abello AS, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and Stallergenes Greer Ltd. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Product

  • Market segments
  • Comparison by Product placement
  • Antihistamines - Market size and forecast 2019-2024
  • Intranasal corticosteroids - Market size and forecast 2019-2024
  • Immunotherapies - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Product

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • South America - Market size and forecast 2019-2024
  • MEA - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher-priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Alcon Inc.
  • ALK-Abello AS
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Stallergenes Greer Ltd.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 5
  • 5.Key Finding 6
  • 6.Key Finding 7
  • 7.Key Finding 8
  • 8.Market in focus
  • 10.Parent market
  • 13.Market characteristics
  • 15.Offerings of vendors included in the market definition
  • 17.Market segments
  • 22.Global - Market size and forecast 2019 - 2024 ($ million)
  • 23.Global market: Year-over-year growth 2019 - 2024 (%)
  • 24.Five forces analysis 2019 & 2024
  • 25.Bargaining power of buyers
  • 26.Bargaining power of suppliers
  • 27.Threat of new entrants
  • 28.Threat of substitutes
  • 29.Threat of rivalry
  • 30.Market condition - Five forces 2019
  • 31.Product placement - Market share 2019-2024 (%)
  • 32.Comparison by Product placement
  • 33.Antihistamines - Market size and forecast 2019-2024 ($ million)
  • 34.Antihistamines - Year-over-year growth 2019-2024 (%)
  • 35.Intranasal corticosteroids - Market size and forecast 2019-2024 ($ million)
  • 36.Intranasal corticosteroids - Year-over-year growth 2019-2024 (%)
  • 37.Immunotherapies - Market size and forecast 2019-2024 ($ million)
  • 38.Immunotherapies - Year-over-year growth 2019-2024 (%)
  • 39.Others - Market size and forecast 2019-2024 ($ million)
  • 40.Others - Year-over-year growth 2019-2024 (%)
  • 41. Market opportunity by Product
  • 42.Customer landscape
  • 43.Market share by geography 2019-2024 (%)
  • 44.Geographic comparison
  • 45.North America - Market size and forecast 2019-2024 ($ million)
  • 46.North America - Year-over-year growth 2019-2024 (%)
  • 47.Europe - Market size and forecast 2019-2024 ($ million)
  • 48.Europe - Year-over-year growth 2019-2024 (%)
  • 49.APAC - Market size and forecast 2019-2024 ($ million)
  • 50.APAC - Year-over-year growth 2019-2024 (%)
  • 51.South America - Market size and forecast 2019-2024 ($ million)
  • 52.South America - Year-over-year growth 2019-2024 (%)
  • 53.MEA - Market size and forecast 2019-2024 ($ million)
  • 54.MEA - Year-over-year growth 2019-2024 (%)
  • 55.Key leading countries
  • 56.Market opportunity by geography ($ million)
  • 57.Impact of drivers and challenges
  • 58.Vendor landscape
  • 60.Landscape disruption
  • 62.Industry risks
  • 64.Vendors covered
  • 66.Market positioning of vendors
  • 67.Alcon Inc. - Overview
  • 68.Alcon Inc. - Business segments
  • 69.Alcon Inc. - Key offerings
  • 70.Alcon Inc. - Key customers
  • 71.Alcon Inc. - Segment focus
  • 72.ALK-Abello AS - Overview
  • 73.ALK-Abello AS - Product and service
  • 74.ALK-Abello AS - Key offerings
  • 75.ALK-Abello AS - Key customers
  • 76.ALK-Abello AS - Segment focus
  • 77.Dr. Reddy's Laboratories Ltd. - Overview
  • 78.Dr. Reddy's Laboratories Ltd. - Business segments
  • 79.Dr. Reddy's Laboratories Ltd. - Key offerings
  • 80.Dr. Reddy's Laboratories Ltd. - Key customers
  • 81.Dr. Reddy's Laboratories Ltd. - Segment focus
  • 82.GlaxoSmithKline Plc - Overview
  • 83.GlaxoSmithKline Plc - Business segments
  • 84.GlaxoSmithKline Plc - Key offerings
  • 85.GlaxoSmithKline Plc - Key customers
  • 86.GlaxoSmithKline Plc - Segment focus
  • 87.Glenmark Pharmaceuticals Ltd. - Overview
  • 88.Glenmark Pharmaceuticals Ltd. - Product and service
  • 89.Glenmark Pharmaceuticals Ltd. - Key offerings
  • 90.Glenmark Pharmaceuticals Ltd. - Key customers
  • 91.Glenmark Pharmaceuticals Ltd. - Segment focus
  • 92.Merck & Co. Inc. - Overview
  • 93.Merck & Co. Inc. - Business segments
  • 94.Merck & Co. Inc. - Key offerings
  • 95.Merck & Co. Inc. - Key customers
  • 96.Merck & Co. Inc. - Segment focus
  • 97.Novartis AG - Overview
  • 98.Novartis AG - Business segments
  • 99.Novartis AG - Key offerings
  • 100.Novartis AG - Key customers
  • 101.Novartis AG - Segment focus
  • 102.Pfizer Inc. - Overview
  • 103.Pfizer Inc. - Business segments
  • 104.Pfizer Inc. - Key offerings
  • 105.Pfizer Inc. - Key customers
  • 106.Pfizer Inc. - Segment focus
  • 107.Sanofi - Overview
  • 108.Sanofi - Business segments
  • 109.Sanofi - Key offerings
  • 110.Sanofi - Key customers
  • 111.Sanofi - Segment focus
  • 112.Stallergenes Greer Ltd. - Overview
  • 113.Stallergenes Greer Ltd. - Product and service
  • 114.Stallergenes Greer Ltd. - Key offerings
  • 115.Stallergenes Greer Ltd. - Key customers
  • 116.Stallergenes Greer Ltd. - Segment focus
  • 118.Currency conversion rates for US$
  • 119.Research Methodology
  • 120.Validation techniques employed for market sizing
  • 121.Information sources
  • 122. List of abbreviations